At the event in Vienna, Austria, Addex Therapeutics CEO Tim Dyer discussed the company’s pipeline and strategy within the high-risk CNS landscape. Addex’s lead compound, dipraglurant, is being developed as a treatment for Parkinson’s disease levodopa-induced dyskinesia. Dyer talked about moving the drug into Phase III trials and preparing for commercial success.
BIO-Europe Spring 2019: Addex CEO: There’s Space For Better Therapies In Parkinson’s
At the recent BIO-Europe Spring partnering conference, Tim Dyer, CEO of Addex Therapeutics, spoke to Lucie Ellis, executive editor of In Vivo, about the company’s small-molecule allosteric modulators for central nervous system disorders.

More from Business
- • By
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
- • By
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
More from Scrip
- Sponsored by :
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
